2016 American Transplant Congress

June 11-15, 2016 in Boston, MA

View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions.

A. Masoumi,¹ R. Barth,² J. LaMattina,² D. Bruno,² L. Hebert,¹ N. Schluterman,³ S. Hanish.²
Landscape of Hypertension Treatment in Former Kidney Donors.

L. Ferrara, O. Sanchez, D. Berglund, A. Matas, H. Ibrahim.
Laparoscopically Assisted Living Donor Hepatectomy Is Safe and Cost Effective.

M. Akoad, M. Simpson, E. Pomfret.
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.

J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Late Outcome Surrogate Score (LOSS) for Kidney Allograft Failure.

B. Ho, L. Zhao, S. Montag, D. Ladner, M. Abecassis, A. Skaro.
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.

D. Goodall, M. Willicombe, A. McLean, D. Taube.
Late Renal Xenograft Failure Is Antibody-Mediated: Description of the Longest-Reported Survival in Pig-to-Primate Renal Xenotransplantation.

L. Higginbotham,¹ S. Kim,¹ D. Mathews,¹ A. Stephenson,¹ C. Breeden,¹ C. Larsen,¹ M. Ford,¹ K. Newell,¹ A. Tector,² A. Adams.¹
Late-Onset Pneumocystis Jirovecii Pneumonia After Renal Transplantation: A Case-Control Study.

J. Lee,¹ J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ B. Kim,² M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
Latest VCA Statistics in the U.S.

W. Cherikh,¹ H. McGehee,¹ C. Wholley,¹ L. Levin,² S. McDiarmid.³
Learning Curve of Laparoscopic Donor Nephrectomy for Abdominal Transplant Surgery Fellows.

O. Serrano,¹ A. Bangdiwala,² D. Vock,³ V. Kirchner,¹ T. Dunn,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Learning from Cancer: Using D-Lactate for Therapeutic Immunosuppression.

U. Beier,¹ J. Jiao,¹ H. Xiao,¹ A. Angelin,² D. Wallace,² M. Levine,³ W. Hancock.⁴
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.

S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
Left Renal Vein Ligation for Management of Portal Hypoperfusion in Liver Transplantation.

K. Putchakayala, W. Kane, K. Takahashi, M. Rizzari, A. Yoshida, M. Abouljoud.
Lessons Learned Transplanting High KDPI Kidneys Over a Decade: Improvements in Graft Survival Stem from Lower Rates of Early Graft Loss.

S. Sanoff,¹ K. Ravindra, D. Vikraman, U. Patel, D. Sudan, W. Irish.²
Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction.

G. Dreyer,¹ J. de Fijter,¹ D. Briscoe,² K. Daly,² M. Reinders.¹
Life-Years Saved After Pediatric Liver Transplantation.

R. Gruessner, A. Gruessner.
Limited Efficacy of Bortezomib on Desensitization via Rapid Humoral Compensation in a Sensitized Rhesus Model.

J. Kwun,¹ C. Burghuber,¹ N. Iwakoshi,² A. Gibby,² S. Knechtle.¹
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.

T. Sievers, J. Thompson, J. Lake.
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.

K. Ayasoufi, V. Gorbacheva, F. Ran, A. Valujskikh.
Lipid Metabolism and Preservation of Discarded Steatotic Human Livers Using 24 Hours Ex-Vivo Normothermic Machine Perfusion.

Q. Liu, A. Nassar, G. Iuppa, B. Soliman, L. Buccini, M. Blum, T. Okamoto, T. Uso, A. Bennett, W. Baldwin, K. Abu-Elmagd, J. Fung, C. Miller, C. Quintini.
Live Donor Champion Program: Time to Redefine Living Liver Donation.

D. Maluf, A. Sites, M. Donovan, J. Wang, E. Lyster, C. Argo.
Live Donor Kidney Transplantation of the Most Highly Sensitized Patients in the Era of Kidney Paired Donation.

A. Bingaman,¹ F. Wright,¹ M. Kapturczak,¹ L. Shen,¹ C. Murphey.²
Live Donor Liver Transplantation for NASH: The Toronto Experience.

A. Barbas, N. Goldaracena, M. Dib, M. Marquez, G. Sapisochin, D. Al-Adra, I. McGilvray, M. Cattral, P. Greig, D. Grant.
Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence.

N. Goldaracena, G. Sapisochin, A. Barbas, M. Dib, D. Al-Adra, N. Selzner, M. Cattral, P. Greig, L. Lilly, I. McGilvray, G. Levy, A. Ghanekar, E. Renner, D. Grant, M. Selzner.
Live Kidney Donors Have Significant Out-of-Pocket Costs Associated with Donation.

J. Moore, J. Leanza, A. Massie, N. Dagher, D. Segev.
Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

E. Miner,¹ T. Atim,² M. Mamven,² N. Adjekughele,¹ I. Lawal,³ H. Nadey,⁴ O. Egbuna.⁵
Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy?

R. Mohan, J. Patel, M. Kittleson, D. Chang, T. Aintablian, L. Czer, F. Esmailian, J. Kobashigawa.
Liver Graft Rejuvenation Prior to Transplantation: A Bench-to-Bedside Approach.

A. Zarrinpar,¹ B. Ke,¹ H. Ji,¹ E. Reed,² R. Busuttil,¹ J. Kupiec-Weglinski.¹
Liver Graft Steatosis Associates with an Increase of Circulating Immune Response Chemokines.

R. Gehrau, V. Mas, A. Sharma, V. Bontha, D. Maluf.
Liver Ischemia Induces Kupffer Cell Necroptosis to Facilitate Liver Inflammatory Immune Activation.

S. Yue,¹ H. Zhou,^1,2 R. Busuttil,¹ J. Kupiec-Weglinski,¹ X. Wang,² Y. Zhai.¹
Liver Recipient with Renal Dysfunction: Liver Only or Simultaneous Liver-Kidney Transplant?

K. Yadav, T. Pruett, R. Kandaswamy, W. Payne, L. Zhang, S. Chinnakotla.
Liver Transplantation (LT) Using Liver Allografts from Deceased After Cardiac Death (DCD) Donors: Opinions, Practices and Reality.

L. Sher,¹ P. Abt,² Y. Genyk,¹ M. Lo,¹ P. Yan,¹ L. Ji,¹ C. Marsh.³
Liver Transplantation for Propionic Acidemia: A Review of the United States Scientific Registry for Transplant Recipients (SRTR) and Non-US Case Series.

N. Celik, K. Soltys, G. Bond, Q. Sun, G. Vockley, R. Sindhi, G. Mazariegos.
Liver Transplantation in Patients Actively Drinking Less Than 6 Months Before Transplant Presenting with Acute Decompensation: A Single-Center Experience.

H. Monsour, D. Victor, M. Boktour, J. Galati, J. Ontiveros, L. Theriot, R. McFadden, C. Mobley, A. Saharia, S. Gordon-Burroughs, A. Gaber, R. Ghobrial.
Liver-Intestine Candidates Benefit from National Sharing.

E. Edwards,¹ A. Harper, D. Sudan.
Living Donor Kidney Transplant Outcomes Have Improved Over the Last Decade.

A. Nishio Lucar, G. Vranic, D. Keith.
Living Donor Kidney Transplantation: How Do Recipients Benefit Psychologically?

H. Maple,¹ J. Chilcot,² J. Weinman,² N. Mamode.¹
Living Donor Liver Transplant Has Similar Outcome to Deceased Donor Liver Transplant for MELD > 25.

M. Al Sebayel,¹ F. Abaalkhail,^1,2 M. Shoukri,¹ H. Albahili,^1,2 S. Alabbad,¹ W. AlHamoudi,^1,2,3 H. Albeshbeshy,¹ H. Elsiesy.^1,2
Living Donor Liver Transplantation for Children With Biliary Atresia in the Pediatric End-Stage Liver Disease Era: The Role of Age and Insurance Status.

J. Chu,^1,2 R. Annunziato,³ R. Aviles,³ R. Arnon.^1,2
Living Donor Liver Transplantation for Sick Patients with MELD Score ≥ 35.

R.-S. Soong,¹ Y.-C. Wang,¹ C.-H. Cheng,¹ T.-H. Wu,¹ C.-F. Lee,¹ T.-J. Wu,¹ H.-S. Chou,¹ K.-M. Chan,¹ C.-S. Lee,² W.-C. Lee.¹
Living Donor Rates Vary Greatly Among Organ Procurement Organizations in the United States.

D. Keith, A. Nishio Lucar, G. Vranic.
Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance.

C. Thiessen,¹ J. Gannon,¹ D. Dobosz,¹ S. Li,¹ D. Gray,² A. Mussell,² K. Kennedy,³ L. Skrip,¹ E. Gordon,³ P. Reese,² S. Kulkarni.¹
Living Kidney Donor Priorities for Outcomes: A Nominal Group Technique Study.

C. Hanson,^1,2 J. Kanellis,^3,4 G. Wong,^1,2 J. Pinter,² S. Chadban,^5,6 J. Chapman,⁷ J. Craig,^1,2 J. Gill,⁸ A. Garg,⁹ J. Lewis,^1,2 A. Tong.^1,2
Living Related Small Bowel Transplantation in Children – Patient and Graft Survival at 10 Years.

S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,¹ E. Benedetti.¹
Living Related Small Bowel Transplantation in Children, a Single-Center Experience – Growth, Development and Quality of Life 10 Years After Transplant.

S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,⁴ E. Benedetti.¹
Local Infusion of MyD88 Inhibitor Inhibits Ischemia-Reperfusion Kidney Injury.

H. Cho,^1,3 J. Lee,^1,4 H. Kim,^1,2 Y. Han,² B. Kwon,^1,2 S. Park,^1,3 K. Park.⁴
London Criteria for Listing Potential Liver Transplant Jehovah's Witness (JW) Patients. A Single Centre Results of Listing and Liver Transplant (LT) in JW Patients in Canada.

H. Sharma, I. Al-Hasan, K. Pineda-Solis, M. Tun, P. Marotta, D. Quan, M. Levstik.
Long Term Follow Up of Kidney Donors with Asymptomatic Renal Stones.

D. Serur,¹ M. Charlton,² K. Juluru,³ G. Salama,³ E. LoCastro,³ G. Bretzlaff,² C. Hartono.¹
Long Term Heterotopic Cardiac Xenograft Survival from Donor Pigs with Six Gene Modifications.

M. Mohiuddin,¹ A. Singh,¹ J. Chan,¹ P. Corcoran,¹ M. Thomas III,² B. Lewis,² D. Ayares,³ K. Horvath.¹
Long Term Outcome of De-Novo Autoimmune Hepatitis in Pediatric Recipients of Liver Transplantation.

Y. Avitzur,¹ P. McKiernan,² M. Martinez,³ S. Lobritto,³ D. Kelly,² V. Ng,¹ E. Alonso,⁴ U. Ekong.⁵
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.

L. Furian,¹ L. Di Maria,² G. Cappelli,³ M. Carmellini,⁴ G. Spagnoletti,⁵ G. Piredda,⁶ P. Todeschini,⁷ S. Chiaramonte,⁸ G. Tisone.⁹
Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.

R. Crew, S. Patel, H. Morris, M. Chiles, L. Ratner.
Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center.

D. Ramisch,¹ N. Aguirre,¹ F. Moss,² P. Farinelli,¹ R. Fortunato,² L. Gutierrez,² P. Barros Schelotto,¹ H. Fraguas,³ P. Raffaele,² G. Gondolesi.¹
Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.

P. Tabrizian,¹ M. Giacca,¹ J. Prigoff,² E. Chin,² M. Palese,² D. Herron,² A. Arvelakis,¹ D. LaPointe Rudow,¹ S. Florman,¹ R. Shapiro.¹
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.

C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).

J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Long-Term Death-Censored Graft Loss in the DeKAF Study.

A. Matas,¹ A. Fieberg,¹ R. Leduc,¹ F. Cosio,² R. Gaston,³ R. Mannon,³ M. Cecka,⁴ D. Rush,⁷ B. Kasiske,⁵ S. Gourishankar,⁶ J. Connett,¹ J. Grande.²
Long-Term Deterioration of Graft Function (DeKAF) Study: Histologic Interpretation of Cross-sectional vs Prospective Cohorts.

A. Matas,¹ A. Fieberg,¹ L. Hunsicker,² J. Grande,³ For the DeKAF Group.
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.

Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).

R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
Long-Term Islet Xenograft Survival Requires Effective Control of Early Xenogeneic IL-17 Response and Late Xenogeneic IFN-γ Response.

H. Kang,¹ S. Wang,² X. Zhang,³ A. Singh,⁵ L. Zhang,¹ W. Suarez-Pinzon,⁵ S. Miller,⁴ B. Hering,⁵ X. Luo.^1,3,4
Long-Term Liver Function of Deceased Liver Transplantation Using Hepatitis B Surface Antigen Positive Grafts.

W.-C. Lee,¹ Y.-C. Wang,¹ C.-H. Cheng,¹ T.-H. Wu,¹ C.-F. Lee,¹ R.-S. Soong,¹ T.-J. Wu,¹ H.-S. Chou,¹ K.-M. Chan,¹ C.-S. Lee.²
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.

R. Patel,¹ I. Feurer,¹ S. Karp,¹ L. Gillis,¹ H. Katzenstein,¹ H. Lovvorn III,¹ J. Pietsch,¹ D. Chung, G. Tiao,² D. Hanto.¹
Long-Term Outcomes After Splenectomy for Small-for-Size Syndrome in Live Donor Liver Transplantation.

M. Dib, N. Goldaracena, A. Barbas, M. Marquez, G. Sapisochin, C. Beriault, N. Selzner, I. McGilvray, E. Renner, P. Greig, L. Lilly, A. Ghanekar, M. Cattral, M. Selzner, D. Grant.
Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,¹ J. Medina Pestana,² M. del C Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ A. Matas,⁶ T. Wekerle,⁷ J. Grinyó,⁸ U. Meier-Kriesche,⁹ M. Polinsky,⁹ H. Zhao,⁹ A. Durrbach.¹⁰
Long-Term Outcomes in Pediatric Live-Donor Liver Transplantation.

N. Celik,¹ A. Ganoza,² F. Vyas,¹ J. Squires,³ V. Venkat,³ G. Bond,¹ K. Soltys,¹ R. Sindhi,¹ R. Squires,³ A. Humar,² G. Mazariegos.¹
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.

F. Al Ammary, S. Bae, A. Massie, N. Desai, N. Dagher, E. Kraus, A. Wiseman, D. Segev.
Long-Term Renal Allograft Outcome After Parathyroidectomy.

M. Patecki, I. Scheffner, H. Haller, W. Gwinner.
Long-Term vs Short-Term Valganciclovir Prophylaxis Use for Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Living Related Liver Transplantation.

T. Ueno,¹ H. Yamanaka,¹ Y. Takama,¹ N. Tanaka,¹ Y. Tazuke,¹ K. Bessho,² H. Okuyama.¹
Longitudinal Psychological Outcomes of Living Liver Donors.

Z. Butt,¹ M. Dew,² Q. Liu,³ M. Simpson,⁴ A. Smith,^3,5 J. Zee,³ B. Gillespie,⁵ S. Abbey,⁶ D. Ladner,¹ R. Weinreib,⁷ R. Fisher,⁸ S. Hafliger,⁹ N. Terrault,¹⁰ J. Burton,¹¹ A. DiMartini.²
Low Pretransplant BMI/Weight and Changes in Posttransplant T Cell Exhaustion Levels Are Associated with Viremia/Viral Infection in Pediatric Kidney Transplantation in the First Post-Transplant Year – A Report from the IMPACT Study Consortium.

R. Ettenger,¹ H. Chin,² P. Grimm,³ K. Kesler,² E. Reed,⁴ M. Sarwal,⁵ B. Warshaw,⁶ E. Tsai,¹ A. Kirk.⁷
Low Risk of Cytomegalovirus (CMV) Transmission in Clinical Islet Transplantation.

D. Kabbani,¹ K. Cheung,² P. Senior,² C. Cervera,¹ K. Doucette,¹ J. Preiksaitis.¹
Low-Pressure Pneumoperitoneum in Living Kidney Donors: An Age-Dependent Analysis of Recipient Outcomes.

S. Kulkarni,¹ S. Douglas,² E. Cohen,¹ S. Swift,¹ I. Hall.²
Lower Rates of Living Donor Kidney Transplantation(LD) Among African Americans: What Prevents Higher Rates of Donation?

A. Li, N. Foreman, M. Reissmann, C. Zuttermeister, A. Gilbert, M. Grafals, B. Javaid, S. Ghasemian, P. Abrams, M. Cooper, J. Verbesey.
Lower Renal Graft Function and Accelerated Fibrosis in HIV-Infected Transplant Recipients with Previous HIVAN Compared to Non HIVAN HIV-Positive Transplant Recipients.

M.-N. Peraldi,¹ H. Ayari,¹ M. Burbach,¹ C. Randoux,² E. Pillebout,¹ N. De Castro,³ J.-M. Molina,³ D. Glotz.¹
Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance.

T. Simon, J. Bromberg.
Lysosome Ativity Regulates LG3 Export by Apoptotic Cells.

D. Beillevaire,^1,2,4 J. Turgeon,^1,2,4 E. Boilard,^3,4 M. Dieudé,^1,2,4 M.-J. Hébert.^1,2,4

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z